CEO Resigns Amidst Nasdaq Delisting; Executive Chairman Steps In
Summary
CASI Pharmaceuticals announced the resignation of CEO David Cory, effective March 31, 2026, with Executive Chairman Dr. Wei-Wu He assuming the role of principal executive officer, following the company's recent Nasdaq delisting.
Key Events
-
CEO Resignation Announced
Mr. David Cory has resigned from his role as Chief Executive Officer and as a director of the Company, effective as of March 31, 2026.
-
Executive Chairman Assumes Principal Executive Officer Role
Dr. Wei-Wu He, who was appointed executive chairman on February 19, 2026, will assume the role as the Company's principal executive officer.
-
Follows Recent Nasdaq Delisting
This leadership change occurs shortly after the company announced on February 25, 2026, that it received a delisting decision from Nasdaq.
Analysis
The resignation of CEO David Cory, effective March 31, 2026, is a significant development for CASI Pharmaceuticals, especially coming just days after the company received a delisting decision from Nasdaq. This leadership change, with Executive Chairman Dr. Wei-Wu He stepping in as principal executive officer, suggests a potential shift in strategy or an attempt to stabilize the company during a critical period of operational and financial uncertainty. Investors will be closely watching for further details on the company's plans to address its delisting and future direction under new leadership.
At the time of this filing, CASI was trading at $0.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2M. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.